OncoLab was selected as one of the Top 8 companies in the Startup Spotlight program at BIO Europe 2025, the world’s largest biotechnology partnering conference, and delivered its official presentation on November 4, 2025.
The Startup Spotlight features a carefully chosen group of innovative biotechs from around the world. OncoLab’s selection reflects growing global recognition of its scientific direction and business strategy. Through this opportunity, the company strengthened engagement with European and global pharmaceutical partners and investors, establishing a strong foundation to accelerate the clinical development and commercialization of the ANGel platform.
With this milestone, OncoLab will continue advancing the ANGel platform toward meaningful therapeutic impact for patients worldwide.